Moderna Inc.'s rapid advancement of a vaccine candidate for COVID-19 into clinical trials may help the company establish its messenger RNA platform and advance work on other vaccines in its pipeline.
Executives showcased Moderna's mRNA technology and its potential advantages at a 14 April "Vaccines Day" with investors. CEO Stéphane Bancel...






